Indo Borax & Chemicals Indo Borax & Chemicals will host an earnings conference call on September 2, 2026, to discuss its un-audited financial results for the quarter ended June 30, 2026.

The management team will present both standalone and consolidated figures for Q1FY27 during the session. The call is scheduled for 4:00 pm IST and will be accessible via a dedicated diamond pass link or through universal dial-in numbers provided in the intimation letter.

Call Details

The company issued the intimation on August 27, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Pravin Chavan, Company Secretary & Compliance Officer, signed the disclosure filed with the BSE Ltd and National Stock Exchange of India Ltd.

Participants can join the conference using the following details:

A copy of the intimation has been made available on the company’s official website. Investors and analysts are invited to RSVP with Fortuna PR, the agency managing the event communications.

Indo Borax & Chemicals has moved to expand its portfolio through the acquisition of a controlling stake in specialty chemical manufacturer Kronox Lab Sciences Limited. The company’s Board of Directors, meeting on August 20, 2026, approved the execution of a share purchase agreement to acquire 64.26% of Kronox’s equity shares for an aggregate consideration of ₹246.12 crore.

The transaction involves the purchase of 2.38 crore equity shares from Kronox’s promoters—Ketan Vinodchandra Ramani, Pritesh Vinodchandra Ramani, and Jogindersingh Gianchand Jaswal—at a price of ₹103.22 per share. Zenrock Chemicals Private Limited (ZCPL) is participating in the deal as a person acting in concert with Indo Borax.

Deal Structure and Open Offer

As the acquisition grants Indo Borax control and voting rights exceeding 25% of Kronox’s share capital, the transaction triggers a mandatory open offer under the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 (SAST Regulations).

Indo Borax, along with ZCPL, will make an open offer to public shareholders to acquire up to 95.7 lakh equity shares, representing approximately 25.79% of Kronox’s voting share capital. The offer price for the public shareholders is set at ₹157.27 per equity share, determined in accordance with SAST regulations. The entire consideration for both the private agreement and the open offer will be paid in cash via electronic transfer.

A footnote in the disclosure notes that while the SPA price is ₹103.22, the effective price inclusive of consultancy fees payable by Kronox to the sellers under transition support arrangements is ₹105.87 per share, as calculated under Regulation 8(7) of the SAST Regulations.

Strategic Rationale and Management Commentary

Indo Borax stated that the acquisition aligns with its long-term strategy to diversify its portfolio by investing in sectors demonstrating stability and growth potential. Suresh Kalra, Managing Director and CEO of Indo Borax Chemicals Ltd, described the move as the beginning of a new chapter focused on expansion, diversification, premiumisation, and margin improvement. He noted that Kronox’s rich experience and export presence would strengthen Indo Borax’s offerings and help fortify margins.

Ketan Ramani, Promoter and Director of Kronox Lab Sciences Ltd, thanked stakeholders for their support and highlighted the company's journey from inception to its public listing in 2024. He stated that joining hands with Indo Borax would enable Kronox to accelerate its growth plans, expand its product profile, and explore new avenues. The erstwhile promoters of Kronox Lab Sciences will continue to hold a 9.95% stake and provide transition support post-acquisition.

Target Company Profile

Kronox Lab Sciences Limited is engaged in manufacturing high-purity specialty fine chemicals, including excipients, reagents, buffers, and intermediates, for diversified end-user industries such as pharmaceuticals, nutraceuticals, biotechnology, agrochemicals, and personal care. Based in Vadodara, Gujarat, the target company operates multiple manufacturing units and markets a portfolio of more than 185 products across domestic and export markets.

Kronox reported a turnover of ₹101.22 crore for FY26, showing modest growth from ₹100.19 crore in FY25 and ₹89.86 crore in FY24. The company also reported a profit after tax of approximately ₹28 crore for FY26.

Indo Borax intends to nurture and expand Kronox’s business to maximize value creation for stakeholders. The acquisition is not classified as a related-party transaction, and no promoter or group company holds an interest in the target entity.

The company expects to complete the acquisition within three months of the public announcement. No governmental or regulatory approvals are required for the deal.